Search Results Archives: April 2017

April 28, 2017

Camarillo manufacturer responds to White House call for ideas

From: Camarillo Acorn

Says federal regulations slow business, create red tape

By Rob McCarthy, Special to the Acorn


An executive memo signed Jan. 24 by Trump tasked Ross with investigating the impact of federal regulations on the manufacturing industry. The president has said he wants to keep factory jobs and car makers from leaving the states.


“I guarantee you will receive an ear/eye full of this ever increasing government regulation complexity crisis,” Garcia wrote to the Commerce Department. “We are confident other companies within our industry classification . . . are also facing this.”

April 25, 2017

Remarks by President Trump at Signing of Financial Services Executive Orders

From: The White House


Secretary Mnuchin is a leader in our effort to make America competitive again.  We’re going to make it great again, we’re going to make it strong again, we’re going to make it safe again, and we’re going to make it competitive again.  I’m also issuing two directives that instruct Secretary Mnuchin to review the damaging Dodd-Frank regulations that failed to hold Wall Street firms accountable.  I mean, they’ve done really, in many cases, the opposite of what they were supposed to.  These regulations enshrine “too big to fail” and encourage risky behavior.

April 20, 2017

Trump administration receives 168 comments on ways to cut regulations

From: Aggregates Manager

Kerry Clines

When the Trump administration asked for recommendations on ways the government could cut regulations and make it easier for companies to get their projects approved, the National Stone, Sand & Gravel Association (NSSGA) responded, along with 167 others. According to the Washington Post, three senior administration officials from different departments say that the White House is inclined to accept many of the suggestions.

Some of the most notable comments include the following:

Read Complete Article

April 19, 2017

Interview with Steven Mnuchin: Transcript

From: Financial Times

US Treasury secretary speaks to the FT on tax, economic growth, and North Korea

April 5, 2017

FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars

From: P&T Community

Stephen Barlas

The Food and Drug Administration (FDA) has put one more piece of the biosimilar puzzle in place by issuing final guidance on naming of biological innovator products and bio-similars.1 The agency hewed close to the thinking it first noted in an August 2015 proposed rule and guidance that would “name” a biosimilar by using its non-proprietary name separated from a random four-letter suffix by a hyphen.2,3 That format satisfied almost no one, and brand-name and generics manufacturers, as well as pharmacy groups, got almost none of the changes they requested.